Abatacept - Bristol-Myers Squibb

Drug Profile

Abatacept - Bristol-Myers Squibb

Alternative Names: BMS-188667; BMS-188667SC; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; ONO-4164-IV; ONO-4164-SC; Orencia; Orencia IV; Orencia SC

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Medical Center Groningen; University of Michigan; University of Pittsburgh
  • Class Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Lupus nephritis; Myositis; Sjogren's syndrome
  • Phase II Diffuse scleroderma; Interstitial lung diseases; Nephrotic syndrome
  • Preclinical Inflammation
  • No development reported Ulcerative colitis
  • Discontinued Crohn's disease; Graft-versus-host disease; Multiple sclerosis; Psoriasis; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection

Most Recent Events

  • 13 Jun 2018 Efficacy, adverse events and pharmacodynamcis data from a phase III trial in Lupus nephritis presented at 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 13 Jun 2018 Safety data from two phase II trials in Juvenile rheumatoid arthritis presented at 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 23 Feb 2018 Launched for Juvenile rheumatoid arthritis (Treatment-resistant) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top